Overview

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-20
Target enrollment:
Participant gender:
Summary
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillaiton
Phase:
PHASE2
Details
Lead Sponsor:
Novartis Pharmaceuticals